Racial Disparities in Blood Pressure Control and Treatment Differences in a Medicaid Population, North Carolina, 2005-2006 by Downie, Diane et al.
VOLUME 8: NO. 3 MAY 2011
Suggested citation for this article: Downie DL, Schmid D, 
Plescia MG, Huston SL, Bostrom S, Yow A, et al. Racial 
disparities  in  blood  pressure  control  and  treatment  dif-
ferences in a Medicaid population, North Carolina, 2005-





Racial disparities in prevalence and control of high blood 
pressure are well-documented. We studied blood pressure 
control and interventions received during the course of a 
year in a sample of black and white Medicaid recipients 
with high blood pressure and examined patient, provider, 
and  treatment  characteristics  as  potential  explanatory 
factors for racial disparities in blood pressure control.
Methods
We retrospectively reviewed the charts of 2,078 black and 
1,436 white North Carolina Medicaid recipients who had 
high blood pressure managed in primary care practices 
from July 2005 through June 2006. Documented provider 
responses to high blood pressure during office visits during 
the prior year were reviewed.
Results
Blacks were less likely than whites to have blood pressure 
at goal (43.6% compared with 50.9%, P = .001). Blacks 
above  goal  were  more  likely  than  whites  above  goal  to 
have  been  prescribed  4  or  more  antihypertensive  drug 
classes (24.7% compared with 13.4%, P < .001); to have 
had  medication  adjusted  during  the  prior  year  (46.7% 
compared with 40.4%, P = .02); and to have a documented 
provider response to high blood pressure during office vis-
its (35.7% compared with 30.0% of visits, P = .02). Many 
blacks  (28.0%)  and  whites  (34.3%)  with  blood  pressure 
above goal had fewer than 2 antihypertensive drug classes 
prescribed.
Conclusion
In this population with Medicaid coverage and access to 
primary care, blacks were less likely than whites to have 
their blood pressure controlled. Blacks received more fre-
quent intervention and greater use of combination antihy-
pertensive therapy. Care patterns observed in the usual 
management of high blood pressure were not sufficient to 
achieve treatment goals or eliminate disparities.
Introduction
Racial and ethnic health disparities have become a promi-
nent  issue  in  the  national  debate  about  health  care  in 
the United States and have been particularly well-docu-
mented in cardiovascular disease (CVD), including stroke, 
coronary  heart  disease,  heart  failure,  and  high  blood 
pressure (1-3). Death rates from CVD are higher among 
blacks and have decreased at a slower rate than among 
whites, effectively widening the disparity (4). High blood 
pressure is the single most important modifiable risk fac-
tor for cardiovascular disease, yet blood pressure control is 
achieved in only one-third of all patients with high blood 
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pressure (4-8). Among patients with regular medical care, 
only 48.9% of blacks have their blood pressure adequately 
controlled, compared with 59.7% of whites (4).
A number of factors are important in achieving adequate 
control of high blood pressure, including biological, cultur-
al, social, and health care provider and system factors (9).
Although access to health care has dominated the national 
debate about the inadequacies of the US health care sys-
tem,  racial  and  ethnic  disparities  among  patients  with 
similar  access  to  care  and  similar  socioeconomic  status 
are known to exist (5). Previous studies have found higher 
awareness and treatment of high blood pressure among 
blacks than among whites, but poorer control; demograph-
ics,  socioeconomic  status,  comorbidities,  and  behavioral 
risk factors appear to play little role in explaining these 
racial differences (4,6). Among patients receiving care for 
high blood pressure, provider nonadherence to treatment 
guidelines  or  failure  to  pursue  treatment  goals  aggres-
sively are known to contribute to low attainment of treat-
ment goals for blood pressure. To our knowledge, however, 
no prior studies have explored the role of clinical practice 
patterns in racial disparities in blood pressure control.
Medicaid is the largest provider of health insurance for 
low-income and minority populations in the United States, 
and  Medicaid  patients  have  a  disproportionate  share  of 
cardiovascular risk factor prevalence, uncontrolled blood 
pressure,  and  associated  illness  and  death  (10,11).  We 
reviewed the charts of a representative sample of adult 
Medicaid recipients in North Carolina with diagnosed high 
blood pressure managed in the primary care setting. The 
objectives of this analysis were to 1) identify differences in 
blood pressure control between black and white Medicaid 
recipients with high blood pressure managed in the primary 
care setting; 2) examine whether these differences could be 
explained by differences in demographic factors, comorbidi-
ties, or provider characteristics; and 3) determine whether 
black patients with blood pressure above goal had received 
differential management for high blood pressure compared 
with that of white patients during the prior year.
Methods
Study population
We used Medicaid administrative data to select a repre-
sentative sample of North Carolina Medicaid recipients 
aged 21 years or older with high blood pressure managed 
in the primary care setting. Recipients were enrolled with 
Medicaid for at least 11 months from July 1, 2005, through 
June 30, 2006, and had an office visit with a diagnosis of 
high blood pressure (ICD9 401xx), excluding pregnancy-
induced high blood pressure. We excluded patients who 
had  any  office  visits  with  a  cardiologist  or  endocrinolo-
gist during this time and those receiving dialysis services 
for  end-stage  renal  disease.  This  study  was  performed 
as a quality improvement activity of the North Carolina 
Division  of  Medical  Assistance  and  was  exempted  from 
review  by  the  University  of  North  Carolina  Office  of 
Human Research Ethics.
North  Carolina  had  a  traditional  fee-for-service  (FFS) 
program for Medicaid recipients and 2 managed-care pro-
grams during the study period: Carolina ACCESS (CA-I), 
in which recipients are assigned to a primary care provider 
(PCP), and ACCESS II (CA-II), which additionally incor-
porates community-based care management and quality 
improvement initiatives. PCPs were identified according 
to administrative assignment for eligible patients in the 
CA-I and CA-II systems. For FFS patients, the PCP was 
identified by examining professional services claims sub-
mitted during the eligibility year with the following spe-
cialty type: general or family medicine, internal medicine, 
obstetrics and gynecology, pediatrics, federally qualified 
health center, rural health center, nurse practitioner, or 
health department. The provider who had submitted the 
most claims (or the most recent claim in case of a tie) was 
identified as that patient’s PCP. In Medicaid administra-
tive data, “provider” refers to a single physician or a larger 
practice organization.
To ensure a representative statewide sample and adequate 
sampling from 8 counties planning a high blood pressure 
initiative for CA-II enrollees, we used a stratified cluster 
sampling  design  and  randomly  selected  PCPs  within  4 
sampling strata (CA-II patients in pilot counties, CA-II 
patients in nonpilot counties, CA-I/FFS patients in pilot 
counties, and CA-I/FFS patients in nonpilot counties). We 
excluded providers with fewer than 5 eligible patients. A 
total of 4,046 charts were reviewed from March through 
July 2007. Of these, we excluded 224 patients from analy-
sis because there was no high blood pressure diagnosis in 
the chart; 60 patients because they had no office visit after 
June 30, 2005; and 20 patients because no blood pressure 
measurement was documented. We limited our analyses 
to  patients  identified  as  black  or  white  in  the  medical 
record, or if not available in the record, according to self-VOLUME 8: NO. 3
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reported race in Medicaid enrollment data. We could not 
determine patient race for 3.5% of charts reviewed. The 
final sample included data for 2,078 black and 1,436 white 
patients from a total of 160 providers.
We  abstracted  medical  record  data  from  the  offices  of 
selected PCPs by using an electronic clinical abstraction 
tool  developed  by  Michigan  Peer  Review  Organization 
and the North Carolina Division of Medical Assistance. 
Q Mark Inc (Q Mark Inc, Englewood, Colorado) provided 
trained nurses for the chart abstractions who passed inter-
rater reliability and consistency tests. Reviewers followed 
systematic guidelines and read all summary documents 
in the chart as well as clinic notes and correspondence for 
a 12-month look-back period from the most recent visit. 
Each chart was reviewed by a single reviewer.
PCP  specialty  was  determined  by  self-identification  of 
the billing practice as recorded in Medicaid administra-
tive data. Length of time with PCP was calculated on the 
basis of the earliest service date and the most recent ser-
vice date documented in the chart. Providers located in a 
county with a population density of more than 200 people 
per square mile, according to US Census 2000 data, were 
classified as urban; all others were classified as rural.
Measures
All study analyses were based on medical record documen-
tation. The goal for blood pressure treatment was defined 
as less than 130/80 mm Hg for patients with diabetes and 
less than 140/90 mm Hg for all others, in accordance with 
the Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC 7) (12). A comprehensive, uniform 
dictionary  of  all  clinical  conditions  and  terms  meeting 
study definitions of high blood pressure, diabetes, hyperlip-
idemia, cardiovascular disease (including coronary disease, 
stroke, and peripheral arterial disease), tobacco use, chron-
ic obstructive pulmonary disease, and asthma was used to 
identify the presence of these conditions as documented in 
the medical record. Chronic kidney disease was defined as 
having an estimated glomerular filtration rate (eGFR) <60 
mL/min/1.73 m2 and was calculated by using the isotope 
dilution mass spectrometry (IDMS)-traceable Modification 
of Diet in Renal Disease (MDRD) Study equation from the 
most recent serum creatinine level documented in the med-
ical record. Body mass index (BMI) was calculated from 
most recent weight and height documented in the medical 
record, when available. If no height was recorded in the 
medical record, the sex-specific median height of the study 
population was used to calculate BMI. Tobacco use status, 
creatinine, and weight were not available for 31%, 9%, and 
2% of patients, respectively. Antihypertensive agents listed 
on the patient’s medication regimen at the time of abstrac-
tion were recorded. Combination therapy was defined as 
the use of 2 or more of the following antihypertensive drug 
class  categories:  angiotensin  converting  enzyme  (ACE) 
inhibitors,  angiotensin  receptor  blockers,  beta  blockers, 
calcium channel blockers, thiazide diuretics, other diuret-
ics, vasodilators, and antiadrenergic agents.
Statistical methods
We  used  the  most  recent  blood  pressure  measurement 
available from the patient’s medical chart to assess the 
prevalence  of  above-goal  blood  pressure  in  blacks  com-
pared  with  whites.  Next,  we  examined  the  bivariate 
relationships between race and patient and provider char-
acteristics that may influence blood pressure control. To 
assess potential explanations for racial disparities in blood 
pressure control, we used logistic regression to calculate 
odds ratios (ORs) for the association between blood pres-
sure control and race (black vs white) and expected covari-
ates. First, in the step 1 full model, we tested for contribu-
tions of patient characteristic variables in predicting blood 
pressure  control,  including  sex,  age,  comorbidities,  and 
number of medications. Covariates associated with blood 
pressure control with a P value less than .10 were included 
in  the  final  model.  In  step  2,  we  added  provider  char-
acteristics,  including  PCP  specialty,  rural  versus  urban 
location, number of years of care with current PCP, and 
number of visits to PCP during the prior year. Covariates 
associated with blood pressure control with a P value less 
than .10 were included in the final step 2 model.
To examine the hypothesis that differential treatment pat-
terns may contribute to observed differences in blood pres-
sure  control,  we  analyzed  treatment  characteristics  for 
the subset of black and white patients with blood pressure 
above goal. Treatment characteristics included discussion 
of medication adherence, diet, weight reduction, exercise, 
sodium restriction, and moderation of alcohol; change in 
antihypertensive  medication  regimen  in  the  prior  year; 
and number of antihypertensive drug classes prescribed 
in combination.
We  additionally  examined  provider  response  to  high 
blood pressure during office visits within the year before 
the most recent office visit, up to 5 visits per patient (n = VOLUME 8: NO. 3
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4,812 visits for blacks, n = 2,931 for whites). For visits with 
blood pressure above goal, we examined the likelihood that 
patients had the following care components: 1) documenta-
tion of a lifestyle recommendation (any recommendation 
for medication adherence, diet, weight reduction, exercise, 
sodium restriction, or moderation of alcohol), 2) change 
in antihypertensive medication regimen, and 3) a docu-
mented plan for follow-up care.
To  analyze  data,  we  used  SAS  versions  9.1  and  9.2 
(SAS Institute, Inc, Cary, North Carolina). Weights were 
applied to correct for the unequal chance of being selected 
for  patient  clusters  within  providers  in  the  4  sampling 
strata, and for unit nonresponse. Analyses accounted for 
the clustering of patients within providers and for strati-
fication. For significance testing, the F-adjusted Rao-Scott 
χ2 square and Wald χ2 square tests were used.
Results
The proportion of patients who had met their blood pres-
sure  goal  was  significantly  lower  among  black  patients 
than white patients (43.6% vs 50.9%, P = .001) (Table 1). 
A greater proportion of blacks were women (74% vs 65%, 
P < .01), and age distribution was similar. Although the 
presence of most comorbidities was similar, blacks were 
less likely to have hyperlipidemia, chronic kidney disease, 
chronic obstructive pulmonary disease, asthma, or reac-
tive airway disease, and were less likely to smoke. Whites 
were more likely than blacks to have 8 or more total active 
medications (56.6% vs 46.6%). Looking specifically at anti-
hypertensive medications, however, nearly half (46.7%) of 
blacks were on 3 or more antihypertensive drug classes 
compared with a third (31.3%) of whites. Geographic loca-
tion, length of time with current PCP, and number of office 
visits in the prior year did not differ by race.
In  step  1  of  the  logistic  regression  modeling  (Table  2), 
when controlling for patient characteristics, blacks were 
significantly less likely than whites to have their blood 
pressure controlled (OR = 0.75; 95% confidence interval 
[CI], 0.61-0.93; P = .009). Inclusion of provider characteris-
tics to the model in step 2 had little additional effect on the 
association between race and blood pressure control (OR 
= 0.78; 95% CI, 0.64-0.96; P = .02), and the relationship 
remained significant. In addition to race, diabetes, weight 
status, and PCP specialty other than family practice or 
internal medicine were associated with poor blood pres-
sure control in the final model.
Among patients who had not achieved their blood pressure 
goal (n = 1,157 blacks and n = 688 whites) (Table 3), blacks 
were more likely than whites to have received counsel-
ing regarding sodium restriction (12% vs 8.5%, P = .006), 
whereas other types of lifestyle recommendations (medica-
tion adherence, diet, weight reduction, exercise, and mod-
eration of alcohol) did not differ significantly by race. Only 
47.4%  of  black  and  47.2%  of  white  patients  with  blood 
pressure  above  goal  had  any  documentation  of  lifestyle 
recommendations during the prior year. Use of combina-
tion antihypertensive therapy was more common among 
blacks (P < .001). Blacks were more likely than whites to 
have had a change of antihypertensive medication regi-
men during the prior year (46.7% vs 40.4%, P = .02).
A total of 14,583 office visits were reviewed. Blood pres-
sure was elevated during 4,812 (57.2%) office visits during 
the prior year for blacks, and 2,931 (49.4%) office visits 
for whites (Table 4). During office visits with above-goal 
blood pressure, blacks were significantly more likely than 
whites  to  have  a  documented  lifestyle  recommendation 
(medication  adherence,  diet,  weight  reduction,  exercise, 
sodium  restriction,  or  moderation  of  alcohol)  (17.6%  vs 
13.9%, P = .002) and more likely to have any documented 
intervention (medication change or lifestyle recommenda-
tion) (35.7% vs 30.0%, P = .021). There was no significant 
difference between races in the likelihood of antihyperten-
sive medication change. A follow-up care plan was noted 
during 64.3% of above-goal visits for blacks and 69.1% of 
above-goal visits for whites (P = .08). Planned follow-up 
within 4 weeks was noted for only 27% of these visits for 
both races.
Discussion
In this statewide sample of Medicaid patients with high 
blood  pressure  managed  in  the  primary  care  setting, 
blacks were less likely than whites to have their blood 
pressure controlled. We found that adjusting for observed 
patient  and  provider  characteristics  slightly  attenuated 
the relationship between race and blood pressure control 
but did not completely explain racial differences.
One strength of this study is that the sample is repre-
sentative of a statewide Medicaid population with high 
blood  pressure,  spanning  multiple  systems  of  care  and 
treatment localities. Medicaid recipients are characterized 
by many factors known to be associated with poor blood 
pressure control or poor health outcomes, including low VOLUME 8: NO. 3
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socioeconomic  status  and  higher  prevalence  of  multiple 
comorbidities  (13,14).  Our  findings  are  consistent  with 
prior  observations  that  racial  differences  in  blood  pres-
sure control among treated patients are not explained by 
socioeconomic factors, nonpharmacological management, 
health insurance, or comorbidities (3,4,6). Despite health 
care coverage, access to care, and frequent office visits, an 
unexplained racial disparity in blood pressure control still 
exists.
Provider  characteristics,  and  quality  and  intensity  of 
care have been shown to be significant causes of health 
disparities (3). Differences in blood pressure control may 
conceivably be due to less aggressive care patterns in black 
patients, culturally insensitive care, or other differences in 
counseling and follow-up (15,16). However, in our study, 
disparities in blood pressure control do not appear to be 
explained  by  differential  treatment.  Among  those  with 
blood pressure above goal, blacks were more likely than 
whites to have received counseling about sodium intake, 
to have been prescribed 3 or more blood pressure agents 
in combination, and to have a change of therapy within the 
prior year. Within each visit with high blood pressure, the 
likelihood of medication change and planned follow-up did 
not differ by race, although blacks were more likely than 
whites to receive a therapeutic lifestyle recommendation.
Lack  of  appropriately  aggressive  care,  or  clinical  iner-
tia, has been cited as a cause for suboptimal control of 
chronic disease risk factors across much of the US health 
care system (17). We confirmed considerable evidence of 
clinical inertia for both black and white patients. Fewer 
than half of patients with blood pressure above goal had 
documentation of any lifestyle counseling in the past year. 
During visits with high blood pressure, medical therapy 
was  changed  on  only  1  in  5  opportunities.  In  addition, 
28%  of  black  patients  and  34%  of  white  patients  with 
uncontrolled blood pressure were treated with fewer than 
2 antihypertensive agents, which may not be sufficient to 
achieve blood pressure goals (18).
We were unable to explore many characteristics of patients, 
health  systems,  and  environments  that  may  contribute 
to racial disparities in blood pressure control, including 
health literacy, medication adherence, and barriers to fol-
lowing therapeutic lifestyle recommendations (19). Racial 
differences in the metabolic and hormonal pathogenesis of 
high blood pressure may contribute to the prevalence and 
severity of high blood pressure among blacks, although 
differences in socioeconomic conditions, access to care, and 
health-related knowledge or attitudes are thought to play 
a larger role (20). Researchers have examined the extent 
to  which  perceptions  of  racial/ethnic  discrimination  can 
adversely affect health (21-24). Negative attitudes attrib-
uted to discrimination have been linked to adverse physi-
ologic reactions involving blood pressure, and researchers 
have  hypothesized  that  the  chronic  triggering  of  these 
cardiovascular reactions due to discrimination could lead 
to the development of high blood pressure (22). These reac-
tions may be caused by various factors, including worry 
about blood pressure, care-seeking behavior of patients, 
lack of trust, majority provider behavior toward minority 
patients, or miscommunication between patients and pro-
viders (18,24-27).
This study had several limitations. We may have overes-
timated blood pressure control in this population because 
all patients sampled were receiving primary care services, 
and patients with more complicated disease (those seeing 
cardiologists and endocrinologists and those on dialysis) 
were  excluded.  Our  study  population  had  a  lower  pro-
portion of patients older than 65 years than the source 
Medicaid  population,  probably  because  of  these  exclu-
sions. Generalizability to other populations is also limited. 
Medicaid eligibility requires meeting state-specific thresh-
olds of low income and assets, in addition to categorical 
requirements of being elderly, disabled, or pregnant, or 
having dependent children. Our analyses were limited to 
information obtainable in the medical record and relied on 
the accuracy of clinic blood pressure measurements and 
completeness of chart documentation, which may be par-
ticularly unreliable in assessing the extent of therapeutic 
lifestyle counseling. We counted as evidence of counseling 
any mention of lifestyle factors or medication adherence 
in the visit note.
In summary, the gap between current care and ideal care 
for both black and white Medicaid recipients with high 
blood pressure is substantial, even among patients with 
frequent  access  to  primary  care.  Racial  disparities  in 
blood pressure control are not readily explained by socio-
economic, demographic, or comorbidity differences or by 
provider  characteristics  or  treatment  patterns.  Current 
care patterns are not sufficient to eliminate racial dispari-
ties in blood pressure control or to achieve desired treat-
ment goals. The consequences of ineffective health care for 
high blood pressure, in terms of avoidable cardiovascular 
illness,  death,  and  health  care  costs,  disproportionately 
affect blacks. Emerging models of high blood pressure care, 
incorporating  patient-centered  care  teams  and  planned, VOLUME 8: NO. 3
MAY 2011
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longitudinal stepped care approaches, show promise for 
improving  outcomes  across  all  patient  populations  (27-
30). It cannot be assumed, however, that equal access and 
equal treatment will lead to equal outcomes. Closing the 
gap  of  racial  disparities  may  require  a  more  concerted 
clinical effort for racial minorities and better coordination 
between health care providers and community resources 
that can address cultural and health literacy needs and 
support patient self-management efforts in the home and 
community setting. Further research is needed to guide 
these efforts.
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Tables
Table 1. Blood Pressure Control,a Patient, Provider, and Treatment Characteristics of Medicaid Patients With Hypertension, by Race, 
North Carolina, 2005-2006b
Characteristic
Black (n = 2,078) White (n = 1,436) Total (N = 3,514)
P Valuec  n
Weighted % (95% 
CI) n
Weighted % (95% 
CI) n
Weighted % (95% 
CI)
High blood pressure  1,1 .8 (1.-8.2) 923 . (0.-8.1) 2,078 9.2 (.2-2.1) <.001
Blood pressure at goal 921 3. (0.-.8) 78 0.9 (7.1-.) 1,9 .9 (.2-9.) .001
Age group, y
21-39  371 17.8 (1.2-20.) 22 1. (13.-19.7) 13 17.3 (1.0-19.)
. 0-  1,302 2.3 (9.-.1) 917 .3 (1.3-7.3) 2,219 3.2 (1.0-.)
≥65  0 19.8 (1.-23.3) 277 19.1 (1.9-22.) 82 19. (1.9-22.2)
Sex
Men 22 2.8 (23.2-28.3) 90 3. (31.9-37.3) 1,012 29.8 (27.7-31.8)
<.001
Women 1, 7.2 (71.7-7.8) 9 . (2.7-8.1) 2,02 70.2 (8.2-72.3)
Weight distributiond
Normal (BMI <2 kg/w2) 298 1. (12.-1.) 227 1. (13.-17.) 2 1.0 (13.-1.)
.0 Overweight (BMI 2-29.9 kg/w2) 1 21.9 (19.3-2.) 30 23. (21.0-2.8) 781 22. (20.8-2.3)
Obese (BMI >30 kg/w2) 1,292 3.7 (0.2-7.1) 8 1.0 (8.-3.) 2,137 2. (0.3-.)
Comorbidities and risk factors
Diabetes 802 39. (37.2-2.1) 30 37.9 (3.-1.2) 1,332 38.8 (3.8-0.9) .0
Hyperlipidemia 82 1. (37.7-.) 7 .7 (3.7-9.7) 1,02 3.9 (1.1-9.3) .02
Cardiovascular disease 37 19.2 (1.-21.9) 270 17. (1.2-20.7)  18. (1.2-20.7) .38
Current tobacco usee  39. (3.7-.2) 9 1. (7.0-.9) 1,113 .2 (1.1-9.3) <.001
Chronic kidney disease 
(eGFR<0)f
12 2.7 (22.0-27.) 38 28.7 (2.-30.8) 79 2. (2.-28.) .01
COPD or asthma/reactive  
airway disease
37 17. (1.-19.) 327 22.8 (19.2-2.) 8 19.9 (17.9-21.9) .00
 
Abbreviations: CI, confidence interval; BMI, body mass index; GFR, glomerular infiltration rate; COPD, chronic obstructive pulmonary disease; PCP, primary care 
provider; JNC-7, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressire. 
a  Blood pressure at goal according to JNC-7 standards; <130/80 mm Hg for patients with diabetes; otherwise <10/90 mm Hg (12). 
b Variables with missing data overall and by race are as follows: tobacco use (overall = 1,077, black = 717, and white = 30), chronic kidney disease 
(eGFR<0) (overall = 332, black = 211, and white = 121), and length of time with current PCP (overall = 107, black = 8, and white = 22). Total n for blacks, 
2,078; for whites, 1,3; and overall, 3,1 (no missing data for sex, age group, both blood pressure measures, diabetes, hyperlipidemia, cardiovascular dis-
ease, COPD/asthma, provider location, PCP visits in past year). 
c P value based on F-adjusted Rao-Scott χ2 test comparing black and white patients. 
d Weight distribution for those patients for whom both height and weight were documented in the medical chart. For patients without height, median height of 
the population was used (total n = 3,3; black n = 2,031; white n = 1,12. No weight abstracted for 71 patients). 
e Tobacco use among those who have been screened for tobacco use and whose status was known (total n = 2,37; black n = 1,31; white n = 1,07).  
f Chronic kidney disease for those for whom eGFR was available (total n = 3,182; black n = 1,87; white n = 1,31). 
g Providers located in a county with a population density of more than 200 people per square mile, according to US Census 2000 data, were classified as 
urban; all others were classified as rural. 
h For 107 patients, no first visit date was abstracted. Therefore, length of care with their provider could not be established. 
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Characteristic
Black (n = 2,078) White (n = 1,436) Total (N = 3,514)
P Valuec  n
Weighted % (95% 
CI) n
Weighted % (95% 
CI) n
Weighted % (95% 
CI)
No. of total active medications
0-3 319 1. (12.1-1.9) 13 8.8 (.3-11.3) 3 11.9 (10.3-13.)
<.001 -7 811 38.9 (3.-2.2) 03 3. (31.7-37.3) 1,31 3.9 (3.-39.2)
≥8 98 . (2.-0.8) 799 . (3.-9.8) 1,77 1.2 (.9-2.3)
Provider and treatment characteristics
PCP specialty
General/family practice 971 9. (3.9..3) 82 3.0 (.3-80.) 1,823 .7 (1.0-70.3)
.03 Internal medicine 821 30. (17.-3.7) 80 27. (12.1-3.0) 1,301 29.2 (1.-1.9)
Other/unknown 28 19.8 (8.9-30.8) 10 9. (1.-17.) 390 1.1 (.9-2.3)
Geographic location, by provider countyg
Rural 97 7.3 (3.-71.0)  9.0 (28.9-9.0) 1,23 3. (38.2-8.8)
.21
Urban 1,121 2.7 (29.0-.) 770 1.0 (31.0-71.1) 1,891 . (31.2-1.8)
Length of time with current PCP, yh
>1 y 201 8.7 (.-10.9) 11 7. (.-9.7) 317 8.2 (.-9.9)
.703
1-2 y 71 33.1 (27.1-39.1) 7 31.8 (27.0-3.7) 1,192 32. (27.-37.)
3- y 30 18.8 (1.1-22.) 287 20.7 (17.-2.0) 7 19.7 (1.-22.7)
≥5 y 71 39. (32.1-.7) 3 39.9 (3.7-.0) 1,21 39. (3.1-.1)
No. of PCP visits in past year
1-2 visits 22 13. (11.1-1.7) 137 9.8 (.7-13.0) 399 11.8 (9.7-13.8)
.09 3- visits 9 2.8 (23.3-30.) 32 2.9 (22.3-29.) 921 2. (23.-29.)
≥5 visits 1,27 9.7 (.9-.) 97 .3 (8.-70.1) 2,19 1.8 (7.-.2)
 
Abbreviations: CI, confidence interval; BMI, body mass index; GFR, glomerular infiltration rate; COPD, chronic obstructive pulmonary disease; PCP, primary care 
provider; JNC-7, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressire. 
a  Blood pressure at goal according to JNC-7 standards; <130/80 mm Hg for patients with diabetes; otherwise <10/90 mm Hg (12). 
b Variables with missing data overall and by race are as follows: tobacco use (overall = 1,077, black = 717, and white = 30), chronic kidney disease 
(eGFR<0) (overall = 332, black = 211, and white = 121), and length of time with current PCP (overall = 107, black = 8, and white = 22). Total n for blacks, 
2,078; for whites, 1,3; and overall, 3,1 (no missing data for sex, age group, both blood pressure measures, diabetes, hyperlipidemia, cardiovascular dis-
ease, COPD/asthma, provider location, PCP visits in past year). 
c P value based on F-adjusted Rao-Scott χ2 test comparing black and white patients. 
d Weight distribution for those patients for whom both height and weight were documented in the medical chart. For patients without height, median height of 
the population was used (total n = 3,3; black n = 2,031; white n = 1,12. No weight abstracted for 71 patients). 
e Tobacco use among those who have been screened for tobacco use and whose status was known (total n = 2,37; black n = 1,31; white n = 1,07).  
f Chronic kidney disease for those for whom eGFR was available (total n = 3,182; black n = 1,87; white n = 1,31). 
g Providers located in a county with a population density of more than 200 people per square mile, according to US Census 2000 data, were classified as 
urban; all others were classified as rural. 
h For 107 patients, no first visit date was abstracted. Therefore, length of care with their provider could not be established. 
Table 1. (continued) Blood Pressure Control, Patient, Provider, and Treatment Characteristics of Medicaid Patients With Hypertension, 
by Race, North Carolina, 2005-2006a
(Continued on next page)VOLUME 8: NO. 3
MAY 2011
10  Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2011/may/10_0070.htm
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position  
of the Centers for Disease Control and Prevention.
Characteristic
Black (n = 2,078) White (n = 1,436) Total (N = 3,514)
P Valuec  n
Weighted % (95% 
CI) n
Weighted % (95% 
CI) n
Weighted % (95% 
CI)
No. of antihypertensive drug classes prescribed
0-1 722 32.3 (28.8-3.8) 07 0. (3.3-.9) 1,329 3.1 (33.1-39.1)
<.001
2 13 20.9 (28.9-3.8) 370 28.0 (21.-3.) 783 2.1 (19.7-28.)
3 9 2. (23.2-27.9) 27 19.3 (17.-21.1) 772 22.7 (21.0-2.)
≥4 7 21.2 (18.-2.1) 183 12.0 (9.0-1.0) 30 17.1 (1.3-19.9)
 
Abbreviations: CI, confidence interval; BMI, body mass index; GFR, glomerular infiltration rate; COPD, chronic obstructive pulmonary disease; PCP, primary care 
provider; JNC-7, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressire. 
a  Blood pressure at goal according to JNC-7 standards; <130/80 mm Hg for patients with diabetes; otherwise <10/90 mm Hg (12). 
b Variables with missing data overall and by race are as follows: tobacco use (overall = 1,077, black = 717, and white = 30), chronic kidney disease 
(eGFR<0) (overall = 332, black = 211, and white = 121), and length of time with current PCP (overall = 107, black = 8, and white = 22). Total n for blacks, 
2,078; for whites, 1,3; and overall, 3,1 (no missing data for sex, age group, both blood pressure measures, diabetes, hyperlipidemia, cardiovascular dis-
ease, COPD/asthma, provider location, PCP visits in past year). 
c P value based on F-adjusted Rao-Scott χ2 test comparing black and white patients. 
d Weight distribution for those patients for whom both height and weight were documented in the medical chart. For patients without height, median height of 
the population was used (total n = 3,3; black n = 2,031; white n = 1,12. No weight abstracted for 71 patients). 
e Tobacco use among those who have been screened for tobacco use and whose status was known (total n = 2,37; black n = 1,31; white n = 1,07).  
f Chronic kidney disease for those for whom eGFR was available (total n = 3,182; black n = 1,87; white n = 1,31). 
g Providers located in a county with a population density of more than 200 people per square mile, according to US Census 2000 data, were classified as 
urban; all others were classified as rural. 
h For 107 patients, no first visit date was abstracted. Therefore, length of care with their provider could not be established. 
Table 2. Odds of Blood Pressure at Goal Among Black Versus White Medicaid Patients With Hypertension, North Carolina, 2005-
2006 
Characteristica
Step 1: Patient Characteristics Step 2: Treatment Characteristics
Full Model Final Model Full Model Final Model
Odds Ratio (95% 
CI)a P Valuea
Odds Ratio (95% 
CI)a P Valuea
Odds Ratio (95% 
CI)a P Valuea
Odds Ratio (95% 
CI)a P Valuea
Patient
Race (black vs white) 0.78 (0.-0.9) .02 0.7 (0.1-0.93) .009 0.79 (0.-0.97) .02 0.78 (0.-0.9) .02
Age 1.00 (0.99-1.00) .39 NC NC NC NC NC NC
Sex (men vs women) 1.0 (0.82-1.37) . NC NC NC NC NC NC
 
Abbreviations: CI, confidence interval; NC, not calculated; BMI, body mass index; COPD, chronic obstructive pulmonary disease; PCP, primary care provider. 
a Calculated with Wald χ2 test. 
b BMI is calculated as weight in kilograms divided by height in meters squared. 
c Tobacco use among those who have been screened for tobacco use and whose status was known (total, n = 2,37; black, n = 1,31; white, n = 1,07). 
d Chronic kidney disease for those for whom eGFR was available (total, n = 3,182; black, n = 1,87; white, n = 1,31). 
e Providers located in a county with a population density of more than 200 persons per square mile, according to US Census 2000 data, were classified as 
urban; all others were classified as rural. 
f For 107 patients, no first visit date was abstracted. Therefore, length of care period with their provider could not be established. 
Table 1. (continued) Blood Pressure Control, Patient, Provider, and Treatment Characteristics of Medicaid Patients With Hypertension, 
by Race, North Carolina, 2005-2006a
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Characteristica
Step 1: Patient Characteristics Step 2: Treatment Characteristics
Full Model Final Model Full Model Final Model
Odds Ratio (95% 
CI)a P Valuea
Odds Ratio (95% 
CI)a P Valuea
Odds Ratio (95% 
CI)a P Valuea
Odds Ratio (95% 
CI)a P Valuea
Weight (vs BMI <25)b
Overweight (BMI 2-
29.9 kg/w2)
0.9 (0.7-1.2) .7 0.88 (0.70-1.11) .28 0.8 (0.8-1.08) .20 0.88 (0.70-1.11) .29
Obese (BMI ≥30 
kg/w2)
0.7 (0.9-0.97) .03 0.7 (0.0-0.91) .00 0.7 (0.0-0.91) .00 0.7 (0.2-0.93) .008
Comorbidities and risk factors
Diabetes 0.2 (0.18-0.32) <.001 0.2 (0.21-0.31) <.001 0.2 (0.20-0.31) <.001 0.2 (0.21-0.31) <.001
Hyperlipidemia 1.00 (0.82-1.21) .97 NC NC NC NC NC NC
Cardiovascular disease 0.8 (0.70-1.0) .13 NC NC NC NC NC NC
Current tobacco usec 1.12 (0.91-1.38) .28 NC NC NC NC NC NC
Chronic kidney disease 
(eGFR <0)d
0.8 (0.72-1.0) .12 NC NC NC NC NC NC
COPD or asthma/reac-
tive airway disease
0.9 (0.72-1.28) .77 NC NC NC NC NC NC
No. of medications 1.03 (1.00-1.0) .03 NC NC NC NC NC NC
Provider and treatment 
PCP specialtye (vs family practice)
Internal medicine 
Specialty
NC NC NC NC 0.9 (0.73-1.27) .78 0.9 (0.73-1.2) .7
Other/unknown  
specialty
NC NC NC NC 0.8 (0.1-0.90) .007 0.8 (0.2-0.90) .007
Rural vs urbane NC NC NC NC 1.0 (0.8-1.32) .3 NC NC
Time with PCP,f 
<1 year of care (vs 
> y)
NC NC NC NC 0.89 (0.8-1.17) .0 NC NC
1 to <3 y of care (vs 
> y)
NC NC NC NC 1.00 (0.83-1.21) .99 NC NC
3 to < y of care (vs 
> y)
NC NC NC NC 1.20 (0.9-1.3) .1 NC NC
 
Abbreviations: CI, confidence interval; NC, not calculated; BMI, body mass index; COPD, chronic obstructive pulmonary disease; PCP, primary care provider. 
a Calculated with Wald χ2 test. 
b BMI is calculated as weight in kilograms divided by height in meters squared. 
c Tobacco use among those who have been screened for tobacco use and whose status was known (total, n = 2,37; black, n = 1,31; white, n = 1,07). 
d Chronic kidney disease for those for whom eGFR was available (total, n = 3,182; black, n = 1,87; white, n = 1,31). 
e Providers located in a county with a population density of more than 200 persons per square mile, according to US Census 2000 data, were classified as 
urban; all others were classified as rural. 
f For 107 patients, no first visit date was abstracted. Therefore, length of care period with their provider could not be established. 
Table 2. (continued) Odds of Blood Pressure at Goal Among Black Versus White Medicaid Patients With Hypertension, North 
Carolina, 2005-2006 
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Characteristica
Step 1: Patient Characteristics Step 2: Treatment Characteristics
Full Model Final Model Full Model Final Model
Odds Ratio (95% 
CI)a P Valuea
Odds Ratio (95% 
CI)a P Valuea
Odds Ratio (95% 
CI)a P Valuea
Odds Ratio (95% 
CI)a P Valuea
No. of PCP visits
1-2 (vs >) NC NC NC NC 0.7 (0.2-1.0) .101 NC NC
3- (vs >) NC NC NC NC 0.91 (0.7-1.10) .32 NC NC
 
Abbreviations: CI, confidence interval; NC, not calculated; BMI, body mass index; COPD, chronic obstructive pulmonary disease; PCP, primary care provider. 
a Calculated with Wald χ2 test. 
b BMI is calculated as weight in kilograms divided by height in meters squared. 
c Tobacco use among those who have been screened for tobacco use and whose status was known (total, n = 2,37; black, n = 1,31; white, n = 1,07). 
d Chronic kidney disease for those for whom eGFR was available (total, n = 3,182; black, n = 1,87; white, n = 1,31). 
e Providers located in a county with a population density of more than 200 persons per square mile, according to US Census 2000 data, were classified as 
urban; all others were classified as rural. 
f For 107 patients, no first visit date was abstracted. Therefore, length of care period with their provider could not be established. 
Table 3. Treatment Characteristics for Medicaid Patients at Above Goal Blood Pressure,a by Race, North Carolina, 2005-2006 
Treatment Characteristic
Black (n = 1,157) White (n = 688)
P Valueb n
Weighted % (95% 
CI) n
Weighted % (95% 
CI)
PCP discussed the following topics during the year
Medication adherence 19 1.0 (11.8-18.2) 7 12.1 (7.7-1.) .22
Diet 31 28. (22.9-3.3) 210 30. (23.3-38.0) .3
Weight reduction 10 13.8 (9.90-17.7) 11 1.7 (13.1-20.2) .18
Exercise 23 22. (17.3-27.9) 10 21.8 (17.2-2.3) .70
Sodium restriction 132 12.0 (8.3-1.7) 7 8. (.9-11.1) .00
Moderation of alcohol 3 2. (0.3-.0) 20 2.0 (0.0-.0) .2
Any lifestyle recommendation was providedc
No 0 2. (.-8.8) 37 2.8 (.-8.7)
.97
Yes 17 7. (1.2-3.) 313 7.2 (1.3-3.2)
Number of antihypertensive drug classes prescribed
0-1 32 28.0 (2.-31.) 2 3.3 (27.1-1.)
<.001
2 233 20.8 (18.1-23.) 193 30.9 (22.-39.3)
3 287 2. (23.8-29.) 10 21.3 (18.3-2.)
≥4  28 2.7 (21.-27.7) 100 13. (9.-17.2)
Change in antihypertensive medication regimen in 
the prior year
2 .7 (1.9-1.) 283 0. (3.-.2) .02
 
Abbreviation: CI, confidence interval; PCD, primary care provider. 
a High blood pressure was defined as ≥140/90 mm Hg and ≥130/80 mm Hg for patients with diabetes (12). 
b Calculated with F-adjusted Rao-Scott χ2 test. 
c Includes any documentation that medication adherence, diet, weight reduction, exercise, sodium restriction, or moderation of alcohol was addressed. 
Table 2. (continued) Odds of Blood Pressure at Goal Among Black versus White Medicaid Patients With Hypertension, North Carolina, 
2005-2006 
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Treatment Characteristic
Black (n = 1,157) White (n = 688)
P Valueb n
Weighted % (95% 
CI) n
Weighted % (95% 
CI)
Screened for the following risk factors
Diabetes 1,10 9.3 (9.8-97.9) 8 9.0 (92.8-97.2) .280
Cholesterol 93 82. (79.0-8.9) 8 8.2 (81.1-89.3) .300
Family history 83 .1 (.2-.0) 21 .2 (.7-7.7) .03
Smoking 7 8.7 (1.0-7.) 11 7.0 (.-82.7) .282
Obesity 27 22.3 (1.-29.2) 182 27.8 (21.-3.0) .072
 
Abbreviation: CI, confidence interval; PCD, primary care provider. 
a High blood pressure was defined as ≥140/90 mm Hg and ≥130/80 mm Hg for patients with diabetes (12). 
b Calculated with F-adjusted Rao-Scott χ2 test. 
c Includes any documentation that medication adherence, diet, weight reduction, exercise, sodium restriction, or moderation of alcohol was addressed. 
Table 4. Provider Response to High Blood Pressurea During Office Visits, by Race, North Carolina, 2005-2006 
Provider Response
Office Visits With High Blood 
Pressure, Black Patients, n = 4,812 
(57.2%) 
Office Visits With High Blood 
Pressure, White Patients, n = 2,931 
(49.4%)
P Valueb n
Weighted % (95% 
CI)  n
Weighted % (95% 
CI) 
Change in antihypertensive medication regimen 1,0 22. (18.9-2.1) 3 19. (1.3-22.9) .178
Lifestyle recommendation (total)c 83 17. (1.-20.) 13 13.9 (11.-1.2) .002
Visits during which any intervention was noted 
(medication or lifestyle recommendation)
1,83 3.7 (30.9-0.) 8 30.0 (2.-33.) .021
Any plan for follow-up
Yes 3,01 .3 (.9-71.) 1,979 9.1 (.-73.7) .083
No 1,71 3.7 (28.-3.1) 92 30.9 (2.3-3.)
Follow-up plan within 4 weeks
Yes 1,298 27.0 (23.7-30.2) 802 27.1 (23.-30.8) .9
No 3,1 73.0 (9.8-7.3) 2,129 72.9 (9.2-7.)
 
Abbreviation: CI, confidence interval. 
a High blood pressure was defined as ≥140/90 mm Hg and ≥130/80 mm Hg for patients with diabetes. 
b Calculated with F-adjusted Rao-Scott χ2 test. 
c Includes any documentation that medication adherence, diet, weight reduction, exercise, sodium restriction, or moderation of alcohol was addressed.
Table 3. (continued) Treatment Characteristics for Medicaid Patients at Above Goal Blood Pressure,a by Race, North Carolina, 2005-
2006 